The Patents Court (Birss J) held that medac’s patent EP (UK) 2 046 332 relating to the use of a formulation of methotrexate at a concentration of about 50 mg/ml for the treatment of individuals with inflammatory autoimmune diseases such as rheumatoid arthritis (RA) by subcutaneous injection, was obvious over one of the prior art citations.  The Court also considered the possibility of a squeeze between plausibility and inventive step  Finally, the Judge stated that arguments of lack of inventive step over the common general knowledge alone should be approached with a degree of skepticism.

A full summary of this case has been published on Kluwer IP Law.



To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law

The 2022 Future Ready Lawyer survey showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.

Kluwer IP Law
This page as PDF